Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Revenue: 2009-2025

Historic Revenue for Gyre Therapeutics (GYRE) over the last 14 years, with Sep 2025 value amounting to $30.6 million.

  • Gyre Therapeutics' Revenue rose 19.92% to $30.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $107.3 million, marking a year-over-year increase of 2.13%. This contributed to the annual value of $105.8 million for FY2024, which is 6.78% down from last year.
  • Gyre Therapeutics' Revenue amounted to $30.6 million in Q3 2025, which was up 14.17% from $26.8 million recorded in Q2 2025.
  • Gyre Therapeutics' 5-year Revenue high stood at $101.5 million for Q4 2022, and its period low was $794,000 during Q1 2022.
  • For the 3-year period, Gyre Therapeutics' Revenue averaged around $27.1 million, with its median value being $27.1 million (2023).
  • In the last 5 years, Gyre Therapeutics' Revenue crashed by 91.04% in 2021 and then soared by 4,059.67% in 2022.
  • Gyre Therapeutics' Revenue (Quarterly) stood at $2.4 million in 2021, then soared by 4,059.67% to $101.5 million in 2022, then crashed by 73.25% to $27.1 million in 2023, then grew by 2.67% to $27.9 million in 2024, then climbed by 19.92% to $30.6 million in 2025.
  • Its Revenue was $30.6 million in Q3 2025, compared to $26.8 million in Q2 2025 and $22.1 million in Q1 2025.